Summary
Centene Corporation (CNC) filed an 8-K on May 29, 2024, to provide updates ahead of their investor meetings and the Bernstein Strategic Decisions Conference. The company is expected to reaffirm its full-year 2024 guidance for adjusted diluted EPS to be greater than $6.80 and a consolidated health benefits ratio between 87.3% and 87.9%. While reaffirming guidance, Centene highlighted some key intra-quarter insights that warrant investor attention. Specifically, the company noted higher-than-expected claims receipts in April and early May for its Medicaid segment, signaling continued elevated medical costs in this area, although a significant portion of Medicaid rate changes are anticipated between July and October 2024. Conversely, Centene anticipates strong performance in its Marketplace segment for 2024, including favorable risk adjustment outperformance from 2023. The Medicare segment is performing as expected. Importantly, the company's adjusted diluted EPS guidance now incorporates an estimated $125 million provision for premium deficiency reserves related to 2025 Medicare Advantage bids, to be recognized in the fourth quarter of 2024.
Key Highlights
- 1Reaffirmation of 2024 full-year adjusted diluted EPS guidance of greater than $6.80.
- 2Reaffirmation of 2024 full-year consolidated health benefits ratio range of 87.3% to 87.9%.
- 3Higher than expected claims receipts and medical costs observed in the Medicaid segment during April and early May 2024.
- 4Anticipated strong performance in the Marketplace segment for 2024, including favorable 2023 risk adjustment outperformance.
- 5Medicare segment is on track with 2024 expectations.
- 6Inclusion of a projected $125 million premium deficiency reserve for 2025 Medicare Advantage bids within the full-year EPS guidance, impacting Q4 2024.
- 7Expectation of strong consolidated premium, service revenue, and investment income for Q2 and the remainder of 2024.